Compass Pathways (NASDAQ:CMPS), a unicorn company in the psychedelics space, has been granted its fourth patent by the US Patent and Trademark Office. The company’s flagship phase 2 research program ...
Rahul Malhotra is a Weekend News Writer for Collider. From Francois Ozon to David Fincher, he'll watch anything once. He has been writing for Collider for over two years, and has covered everything ...
Rahul Malhotra is a Weekend News Writer for Collider. From Francois Ozon to David Fincher, he'll watch anything once. He has been writing for Collider for over two years, and has covered everything ...
Psychedelics biotech company Compass Pathways (NASDAQ:CMPS) has purchased an intellectual property portfolio that includes patent applications for a variety of psychedelic and empathogenic substances.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback